The Oncology Institute Inc Stock Price, News & Analysis

The Oncology Institute (NASDAQ: TOI) has partnered with Protocol Behavioral Health to integrate mental health services into cancer care delivery. The collaboration aims to address the significant mental health challenges faced by cancer patients, with research showing that approximately 30% of cancer patients experience depression or anxiety.

Through this partnership, TOI patients will receive immediate access to specialized mental health services, offered in multiple languages and fully integrated into their cancer treatment plans. The partnership utilizes the Collaborative Care Model (CoCM), an evidence-based framework for team-based care delivery that has been shown to improve treatment adherence, quality of life, and patient satisfaction.

The Oncology Institute (NASDAQ: TOI) has reported significant Medicare savings of $1.1 million during Performance Period 2 of the CMS Enhancing Oncology Model (EOM) through its California professional corporation. The company achieved savings of over $3,500 per patient episode and earned maximum scores for reducing avoidable emergency department visits and hospital admissions.

The success was attributed to TOI's High Value Cancer Care program, featuring Health Care Coaches and 24/7 symptom management support. This performance builds on TOI's previous achievements in CMS's Oncology Care Model, where it exceeded quality standards and generated multi-million-dollar Medicare savings.

The Oncology Institute (NASDAQ: TOI) has announced the launch of its Lung Cancer Center of Excellence in Fort Lauderdale, Florida. The center will be led by renowned thoracic oncologist Dr. Edgardo S. Santos Castillero, an internationally recognized expert in the field.

The new center aims to provide advanced cancer treatments and clinical trials in a community-based setting, making high-quality care more accessible to Florida patients. Dr. Santos brings extensive experience from leadership roles at prestigious institutions including Tulane University and the University of Miami/Sylvester Comprehensive Cancer Center.

This initiative aligns with TOI's mission to expand access to value-based oncology care while reducing financial burden for patients and payors.

The Oncology Institute (NASDAQ: TOI) has announced a strategic partnership with Doctors HealthCare Plans to enhance oncology care management in South Florida. TOI will provide delegated utilization management services and clinical advisory support for the Medicare Advantage plan's members.

Under this collaboration, TOI will manage oncology services using its clinical protocols, medical director oversight, and technology-enabled workflows. The partnership aims to support optimal oncology benefit design and evidence-based care pathways, building on TOI's successful track record of managing medical cost risk across multiple states.

The partnership focuses on ensuring patients receive appropriate care while improving outcomes and maintaining cost effectiveness in the healthcare system.

The Oncology Institute (NASDAQ: TOI) reported strong Q2 2025 financial results, with consolidated revenue reaching $119.8 million, up 21.5% year-over-year. The company's pharmacy business showed exceptional growth of over 40%, while adding 50,000 new capitated lives.

Key financial metrics include gross profit of $17.5 million (up 34.4%), net loss of $17.0 million, and Adjusted EBITDA of $(4.1) million. TOI reaffirmed its full-year 2025 guidance, expecting revenue between $460-480 million and targeting the higher end of this range. The company anticipates reaching Adjusted EBITDA positivity by the end of 2025.

Strategic developments include planned expansion in Florida markets and a new capitation relationship with Silver Summit Health Plan in Nevada. TOI also welcomed new executive appointments to strengthen its clinical and administrative leadership.

The Oncology Institute (NASDAQ: TOI), one of the largest value-based oncology groups in the US, announced significant leadership changes to its Board of Directors. Richard Barasch will retire as Chairman of the Board, effective August 12, 2025, with Anne McGeorge, current Board Member and Audit Committee Chair, succeeding him.

McGeorge brings over 35 years of healthcare experience, notably having grown Grant Thornton LLP's Global Health Care and Life Sciences Practice into a $250 million global business. She currently serves on multiple boards including Dianthus Therapeutics (NASDAQ: DNTH), Nimbus Therapeutics, and CitiusTech.

Under Barasch's leadership, TOI successfully became a publicly traded company and expanded its business model beyond California.

The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 13, 2025, after market close.

The company will host a conference call at 5:00 p.m. Eastern Time on the same day. Investors can join via phone (1-877-407-0789 for domestic, 1-201-689-8562 for international) or webcast through TOI's Investor Relations website. A replay will be available until August 20, 2025, using passcode 13754165.

The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has appointed Kristin England as its new Chief Administrative Officer (CAO), effective July 7, 2025. In this newly created position, England will be responsible for overseeing Enterprise Central Business Operations and Technology Strategy across TOI's national operations.

England joins TOI with over 20 years of healthcare management experience, previously serving as a senior executive at McKesson's US Oncology Network, where she specialized in revenue cycle optimization and practice management systems improvement. CEO Daniel Virnich emphasized that England's appointment comes at a crucial time as TOI focuses on scaling its MSO model and strengthening its value-based care approach.

The Oncology Institute (NASDAQ: TOI) has announced a significant partnership with SilverSummit Healthplan, becoming the exclusive oncology provider for over 80,000 Medicaid patients in Nevada, effective July 1. This expansion marks an important step in TOI's mission to provide value-based cancer care to underserved communities.

The partnership will operate through three Nevada locations in Las Vegas, Henderson, and Spring Valley, offering comprehensive cancer care services to SilverSummit Healthplan members. This collaboration aligns with TOI's track record of serving Medicaid patients and SilverSummit's commitment to providing high-quality healthcare access to its members.